中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 8
Aug.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(8): 1867-1873

Association of 25-hydro xyvitamin D and ferritin with metabolic associated fatty liver disease and fibrosis-4 index

DOI: 10.3969/j.issn.1001-5256.2023.08.015

  • Department of Gastroenterology, Wuhan Hankou Hospital, Wuhan 430012, China

Research funding:

Key Project of Wuhan Municipal Health Commission (WX20A08)

More Information
  • Corresponding author: LIU Zhiping, xiao6599@sina.com (ORCID: 0000-0002-3447-0356)
  • Received Date: 2022-11-12
  • Accepted Date: 2022-12-12
  • Published Date: 2023-08-20
    Abstract
  •   Objective  To investigate the association of serum 25-hydroxyvitamin D [25(OH)D] and serum ferritin (SF) with metabolic associated fatty liver disease (MAFLD) and fibrosis-4 (FIB-4) index.  Methods  A retrospective analysis was performed for the clinical data of 595 patients who were hospitalized in Department of Gastroenterology, Wuhan Hankou Hospital, from August 2020 to December 2021. Clinical features were compared between 242 patients with MAFLD and 353 patients without MAFLD, and the prevalence rate of MAFLD and SF level were compared between the groups with different 25(OH)D levels. The non-normally distributed continuous data were expressed as M(P25-P75), and the Mann-Whitney U test was used for comparison between two groups; the chi-square test was used for comparison of categorical data between groups. A Spearman correlation analysis was used to investigate the correlation between serum 25(OH)D and SF in different populations; a binary logistic regression analysis was used to investigate the association of 25(OH)D and SF with the risk of MAFLD and FIB-4 index; the receiver operating characteristic (ROC) curves were used to assess the value of 25(OH)D and SF in the diagnosis of liver fibrosis in patients with MAFLD.  Results  Compared with the non-MAFLD patients, the MAFLD patients had a significant reduction in serum 25(OH)D level [15.35(11.26-20.02) vs 21.71(15.39-27.84), Z=-9.761, P < 0.05] and a significant increase in SF level [365.50(251.75-525.00) vs 205.00(112.50-275.00), Z=-13.317, P < 0.05]. The prevalence rate of MAFLD and SF level tended to increase with the reduction in serum 25(OH)D level (Z=75.512, P < 0.05). Serum 25(OH)D level was significantly negatively correlated with SF in MAFLD patients (r=-0.460, P < 0.05). The logistic regression analysis showed that the reduction in serum 25(OH)D level (odds ratio [OR]=0.934, 95% confidence interval [CI]: 0.879-0.992, P=0.028) and the increase in SF level (OR=1.009, 95%CI: 1.006-1.013, P < 0.001) were independent risk factors for MAFLD, and the reduction in serum 25(OH)D level (OR=0.852, 95%CI: 0.752-0.965, P=0.012) was also an independent risk factor for elevated FIB-4 index (> 2.67) in MAFLD patients. The ROC curve analysis showed that serum 25(OH)D, SF, and their combination had an area under the ROC curve of 0.793, 0.829, and 0.851, respectively, in predicting elevated FIB-4 index (> 2.67) in MAFLD patients (all P < 0.05).  Conclusion  Serum 25(OH)D is negatively correlated with SF, and the reduction in serum 25(OH)D and the increase in SF are associated with the risk of MAFLD and elevated FIB-4 index. Serum 25(OH)D and SF levels have a certain value in predicting liver fibrosis in patients with MAFLD.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    LAZARUS JV, MARK HE, ANSTEE QM, et al. Advancing the global public health agenda for NAFLD: A consensus statement[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(1): 60-78. DOI: 10.1038/s41575-021-00523-4.
    [2]
    DU SX, LU LL, GENG N, et al. Association of serum ferritin with non-alcoholic fatty liver disease: A meta-analysis[J]. Lipids Health Dis, 2017, 16(1): 228. DOI: 10.1186/s12944-017-0613-4.
    [3]
    ALI SANGOUNI A, GHAVAMZADEH S, JAMALZEHI A. A narrative review on effects of vitamin D on main risk factors and severity of non-alcoholic fatty liver disease[J]. Diabetes MetabSyndr, 2019, 13(3): 2260-2265. DOI: 10.1016/j.dsx.2019.05.013.
    [4]
    ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
    [5]
    LIN S, HUANG JF, WANG MF, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world[J]. Liver Int, 2020, 40(9): 2082-2089. DOI: 10.1111/liv.14548.
    [6]
    CIARDULLO S, PERSEGHIN G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population[J]. Liver Int, 2021, 41(6): 1290-1293. DOI: 10.1111/liv.14828.
    [7]
    SHAH AG, LYDECKER A, MURRAY K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2009, 7(10): 1104-1112. DOI: 10.1016/j.cgh.2009.05.033.
    [8]
    LIAO XP, ZHANG ZL, ZHANG HH, et al. Application guideline for vitamin D and bone health in adult Chinese(2014 standard edition) vitamin D working group of osteoporosis committee of China gerontological society[J]. Chin J Osteoporos, 2014, 20(9): 1011-1030. DOI: 10.3969/j.issn.1006-7108.2014.09.002.

    廖祥鹏, 张增利, 张红红, 等. 维生素D与成年人骨骼健康应用指南(2014年标准版)[J]. 中国骨质疏松杂志, 2014, 20(9): 1011-1030. DOI: 10.3969/j.issn.1006-7108.2014.09.002.
    [9]
    ZHOU Q, LI JQ, LI XW. Influence of vitamin D deficiency on fibrosis-4 index and disease severity in patients with nonalcoholic steatohepatitis[J]. J Clin Hepatol, 2022, 38(6): 1293-1298. DOI: 10.3969/j.issn.1001-5256.2022.06.015.

    周荃, 李金强, 黎晓武. 维生素D缺乏对非酒精性脂肪性肝炎患者FIB-4指数及病情严重程度的影响[J]. 临床肝胆病杂志, 2022, 38(6): 1293-1298. DOI: 10.3969/j.issn.1001-5256.2022.06.015.
    [10]
    SUN CJ, ZUO XQ, YAO N, et al. Study on the correlation between serum ferritin and non-alcoholic fatty liver disease[J]. Zhejiang J Integr Tradit Chin West Med, 2019, 29(5): 371-375. DOI: 10.3969/j.issn.1005-4561.2019.05.008.

    孙彩娟, 左昔清, 姚娜, 等. 血清铁蛋白与非酒精性脂肪性肝病相关性研究[J]. 浙江中西医结合杂志, 2019, 29(5): 371-375. DOI: 10.3969/j.issn.1005-4561.2019.05.008.
    [11]
    BACCHETTA J, ZARITSKY JJ, SEA JL, et al. Suppression of iron-regulatory hepcidin by vitamin D[J]. J Am Soc Nephrol, 2014, 25(3): 564-572. DOI: 10.1681/ASN.2013040355.
    [12]
    LIU ZP, ZHANG JH, WANG XN, et al. Effect of vitamin D on serum markers of iron metabolism in patients with non-alcoholic fatty liver disease[J]. Tianjin Med J, 2018, 46(12): 1316-1318. DOI: 10.11958/20180847.

    刘志平, 张金华, 王湘宁, 等. 维生素D对非酒精性脂肪性肝病患者铁代谢的影响[J]. 天津医药, 2018, 46(12): 1316-1318. DOI: 10.11958/20180847.
    [13]
    PATEL YA, GIFFORD EJ, GLASS LM, et al. Identifying nonalcoholic fatty liver disease advanced fibrosis in the veterans health administration[J]. Dig Dis Sci, 2018, 63(9): 2259-2266. DOI: 10.1007/s10620-018-5123-3.
    [14]
    MA XH, ZHANG X, YOU Y, et al. Diagnostic value of APRI combined with FIB-4 for significant liver fibrosis in patients with chronic hepatitis B[J]. Chin J Gastroenterol, 2017, 22(9): 544-547. DOI: 10.3969/j.issn.1008-7125.2017.09.007.

    马晓辉, 张新, 游云, 等. APRI、FIB-4联合对慢性乙型肝炎患者显著肝纤维化的诊断价值[J]. 胃肠病学, 2017, 22(9): 544-547. DOI: 10.3969/j.issn.1008-7125.2017.09.007.
    [15]
    YANG BB, CHEN YH, ZHANG C, et al. Low vitamin D status is associated with advanced liver fibrosis in patients with nonalcoholic fatty liver disease[J]. Endocrine, 2017, 55(2): 582-590. DOI: 10.1007/s12020-016-1152-x.
    [16]
    UDOMSINPRASERT W, JITTIKOON J. Vitamin D and liver fibrosis: Molecular mechanisms and clinical studies[J]. Biomed Pharmacother, 2019, 109: 1351-1360. DOI: 10.1016/j.biopha.2018.10.140.
    [17]
    KOWDLEY KV, BELT P, WILSON LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease[J]. Hepatology, 2012, 55(1): 77-85. DOI: 10.1002/hep.24706.
    [18]
    BUZZETTI E, PETTA S, MANUGUERRA R, et al. Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease[J]. Liver Int, 2019, 39(7): 1325-1334. DOI: 10.1111/liv.14096.
    [19]
    YONEDA M, THOMAS E, SUMIDA Y, et al. Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: Proceed with caution[J]. Hepatol Res, 2014, 44(14): E499-E502. DOI: 10.1111/hepr.12327.
    [20]
    ZENG J, FAN JG. Clinical significance of renaming nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1205-1207. DOI: 10.3969/j.issn.1001-5256.2020.06.002.

    曾静, 范建高. 非酒精性脂肪性肝病更名的临床意义[J]. 临床肝胆病杂志, 2020, 36(6): 1205-1207. DOI: 10.3969/j.issn.1001-5256.2020.06.002.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (253) PDF downloads(37) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return